Objective To perform a systematic literature review of the potential association among
molecular markers of inflammation, alterations in body composition, and insulin resistance …

Objective: The phase III GO-FORWARD study examined the efficacy and safety of
golimumab in patients with active rheumatoid arthritis (RA) despite methotrexate therapy …

Background Tumour necrosis factor α (TNFα) inhibitors are frequently used to treat
rheumatoid arthritis, but whether use of a different TNFα inhibitor can improve patient …

Background Many patients with psoriatic arthritis have an inadequate response to tumor
necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via …

Objective To assess the safety and efficacy of golimumab in methotrexate (MTX)–naive
patients with active rheumatoid arthritis (RA). Methods MTX‐naive patients with RA (n= 637) …

Summary Background The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in
psoriatic arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds the IL …

Objective To assess the efficacy, safety, and pharmacology of subcutaneous administration
of golimumab in patients with active rheumatoid arthritis (RA) despite treatment with …

Objective To evaluate the efficacy and safety of ustekinumab in 3 randomized, placebo‐
controlled studies in patients with axial spondyloarthritis (SpA). Studies 1 and 2 included …

Objective To evaluate changes in baseline patient characteristics and entry criteria of
randomised, controlled studies of tumour necrosis factor alpha (TNFα) inhibitors in …

Background Guselkumab, a human monoclonal antibody that binds to the p19 subunit of
interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis …